Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M75,970Revenue $M6,494Net Margin (%)22.3Z-Score6.0
Enterprise Value $M76,692EPS $1.7Operating Margin %27.9F-Score7
P/E(ttm))54.8Cash Flow Per Share $4.4Pre-tax Margin (%)25.7Higher ROA y-yN
Price/Book15.710-y EBITDA Growth Rate %0Quick Ratio5.2Cash flow > EarningsY
Price/Sales11.55-y EBITDA Growth Rate %22.2Current Ratio5.4Lower Leverage y-yN
Price/Cash Flow17.9y-y EBITDA Growth Rate %2.8ROA % (ttm)10.8Higher Current Ratio y-yY
Dividend Yield %0Insider Buy (3m)0ROE % (ttm)25.9Less Shares Outstanding y-yY
Payout Ratio %0Shares Outstanding M801ROI % (ttm)17.8Gross Margin Increase y-yY

Gurus Latest Trades with CELG

Number of guru portfolios checked: 56. (List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
CELGGeorge Soros 2014-06-30 Buy 0.45%$68.45 - $86.8
($75.89)
$ 95.0225%New holding, 688000 sh.688,000
CELGJoel Greenblatt 2014-06-30 Buy 0.07%$68.45 - $86.8
($75.89)
$ 95.0225%New holding, 63980 sh.63,980
CELGRonald Muhlenkamp 2014-06-30 Reduce-1.91%$68.45 - $86.8
($75.89)
$ 95.0225%Reduce -51.74%144,140
CELGRay Dalio 2014-06-30 Sold Out -0.08%$68.45 - $86.8
($75.89)
$ 95.0225%Sold Out0
CELGJohn Burbank 2014-06-30 Sold Out -0.01%$68.45 - $86.8
($75.89)
$ 95.0225%Sold Out0
CELGRay Dalio 2014-03-31 Add0.07%$69.65 - $85.97
($79.51)
$ 95.0220%Add 962.69%142,400
CELGJohn Burbank 2014-03-31 Buy 0.01%$69.65 - $85.97
($79.51)
$ 95.0220%New holding, 1670 sh.3,340
CELGJohn Keeley 2014-03-31 Sold Out $69.65 - $85.97
($79.51)
$ 95.0220%Sold Out0
CELGRonald Muhlenkamp 2013-12-31 Add0.12%$72.25 - $85.39
($79.05)
$ 95.0220%Add 2.87%294,850
CELGRay Dalio 2013-12-31 Buy 0.01%$72.25 - $85.39
($79.05)
$ 95.0220%New holding, 6700 sh.13,400
CELGMario Gabelli 2013-09-30 Add$60.13 - $77.31
($70.14)
$ 95.0236%Add 29.5%20,940
CELGJohn Keeley 2013-09-30 Buy $60.13 - $77.31
($70.14)
$ 95.0236%New holding, 1320 sh.2,640
CELGJohn Hussman 2013-09-30 Sold Out -0.31%$60.13 - $77.31
($70.14)
$ 95.0236%Sold Out0
CELGRonald Muhlenkamp 2013-06-30 Reduce-0.96%$56.1 - $65.09
($60.18)
$ 95.0258%Reduce -21.92%285,770
CELGJoel Greenblatt 2013-06-30 Sold Out -0.01%$56.1 - $65.09
($60.18)
$ 95.0258%Sold Out0
CELGJohn Hussman 2013-03-31 Reduce-0.71%$39.24 - $57.96
($50.79)
$ 95.0287%Reduce -85.25%118,000
CELGJoel Greenblatt 2013-03-31 Reduce-0.17%$39.24 - $57.96
($50.79)
$ 95.0287%Reduce -94.2%4,660
CELGRay Dalio 2013-03-31 Sold Out -0.07%$39.24 - $57.96
($50.79)
$ 95.0287%Sold Out0
CELGJoel Greenblatt 2012-12-31 Add0.16%$35.65 - $41.04
($38.7)
$ 95.02146%Add 989.15%80,314
CELGMario Gabelli 2012-12-31 Add$35.65 - $41.04
($38.7)
$ 95.02146%Add 68.37%17,510
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

CELG is held by these Gurus:

Ticker Guru Name Portfolio Date* Current Shares % of Shares Outstanding % of Total Assets Managed Change from Last Holdings Holding History
CELG George Soros 2014-06-30688,0000.090.45New Buy
CELG Joel Greenblatt 2014-06-3063,9800.010.07New Buy
CELG Mario Gabelli 2014-06-3023,12000.01+7.34%
CELG Ronald Muhlenkamp 2014-06-30144,1400.022.2-51.74%
CELG Ray Dalio 2014-06-30000Sold Out
CELG John Burbank 2014-06-30000Sold Out
Premium Most recent portfolio changes are included for Premium Members only!


CELG: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
LOUGHLIN JAMES JDirector 2014-08-22Sell20,000$91.254.13view
CASEY MICHAEL DDirector 2014-08-14Sell30,000$88.597.26view
KARSEN PERRY Asee remarks 2014-08-04Sell39,104$87.558.53view
BARKER RICHARD WDirector 2014-07-25Sell17,600$87.039.18view
Celgene International Inc10% Owner 2014-07-08Buy200,000$10850.2view
KAPLAN GILLADirector 2014-06-09Sell30,000$80.8117.58view
CELGENE CORP /DE/10% Owner 2014-05-05Buy1,100,000$42.86121.7view
KARSEN PERRY Asee remarks 2014-05-01Sell23,844$73.3929.47view
Celgene European Investment Co10% Owner 2014-04-29Buy294,800$44115.95view
CELGENE CORP /DE/10% Owner 2014-04-14Buy714,286$71257.43view

Press Releases about CELG :

    Quarterly/Annual Reports about CELG:

    News about CELG:

    Articles On GuruFocus.com
    Ken Fisher's Top Increases of the First Quarter Apr 22 2014 
    David Winters' 2013 Letter to Wintergreen Fund Shareholders Mar 05 2014 
    You Can No Longer Ignore Biotech Feb 07 2014 
    Trying to Beat the Market Is a Fool’s Errand Oct 17 2013 
    Insiders Are Buying Idera Pharmaceuticals Sep 19 2013 
    comment on CELG Mar 20 2013 
    Growth Stocks: There Is a Lot of Value in this Market Part 2 Sep 27 2012 
    High frowth cheap in Jun 30 2012 
    52-Week High Companies: CVS, TSM, PM, ROST, CELG Feb 27 2012 
    52-Week High Companies: CELG, MON, ECL, SBUX, NWSA Jan 16 2012 


    More From Other Websites
    Healthy Earnings Growth Sustains Pricey Biotech ETFs Aug 27 2014
    [video] Best performing September stocks Aug 27 2014
    Celgene rose 2.4% Aug 26 2014
    [video] Cramer's Mad Dash: DSW underrated Aug 26 2014
    Stocks Rise As Biotechs Lead; Amazon To Buy Twitch Aug 25 2014
    Stocks Hold Decent Gains; InterMune Deal Sparks Biotechs Aug 25 2014
    Main Indexes Slip From Highs; Biotechs Show Strength Aug 25 2014
    Today's Stocks Driving Success For The Drugs Industry Aug 25 2014
    [video] Pisani: Ideal conditions for stock owners Aug 25 2014
    [video] Gilead 'the drug story': Cramer Aug 25 2014
    Watch For Today's Momo Momentum Stock: Celgene (CELG) Aug 25 2014
    [video] Markets open: What's moving stocks? Aug 25 2014
    Majority Of IBD 50 Firms Strong On Sponsorship Aug 22 2014
    Data on Celgene's Revlimid Published in Oncology Journal Aug 22 2014
    Bristol-Myers, Celgene Pair Up for Oncology Combo Treatments Aug 21 2014
    [video] Cramer's Stop Trading: Gilead Sciences Aug 21 2014
    Celgene Corporation to Present at Investor Conferences in September Aug 21 2014
    Bristol-Myers teams with Celgene to explore new cancer treatments Aug 20 2014
    [$$] Bristol-Myers, Celgene to Collaborate on Cancer-Treatment Study Aug 20 2014
    Bristol-Myers Squibb and Celgene Enter Clinical Collaboration Agreement to Evaluate Immunotherapy... Aug 20 2014

    Add Notes, Comments or Ask Questions

    User Comments

    No comment yet
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    Free 7-day Trial
    FEEDBACK